Regeneron's Next Chapter: Sanofi Talks and a Collaboration Revenue Step-Up

Strong Q2 confirms the commercial engine, but the real signal is the end of the development balance repayment and early but productive Sanofi discussions on follow-on assets.

REGN · Earnings Call · 2026-07-30

A Financial Inflection Point

Regeneron's second quarter 2026 results were strong across the board: total revenues rose 17% to $4.3 billion, Dupixent, EYLEA HD, and Libtayo all posted record quarterly net sales, and non-GAAP EPS grew 11%. But the more consequential development was financial: the company announced it had fully repaid the ~$3.1 billion Sanofi development balance, a burden that had been depressing collaboration revenue for over a year. As CFO Chris Fenimore explained, “We've now fully repaid the Sanofi development balance … Given full repayment of the Sanofi development balance starting in the third quarter, we expect Sanofi collaboration revenue to step up as we record our full share of collaboration profits.” — Christopher Fenimore, Senior Vice President, Finance & Chief Financial Officer · 2026-07-30 This step-up is a major tailwind for the second half of 2026 and beyond, effectively adding hundreds of millions of dollars in annual profit sharing with no incremental cost. The company's commercial portfolio remains robust. Dupixent continued to grow at a 38% constant-currency pace, and EYLEA HD now represents ~60% of the franchise, with sequential demand growth of 24%. Libtayo has become the second most prescribed immunotherapy in first-line non-small cell lung cancer. Revenue is riding a long upward trend, with total revenue having nearly tripled over the past six years, and the current quarter only extends that trajectory.

The Strategic Pivot: Sanofi and the Search for External Growth

Perhaps more important than the numbers is the tone from management. Len Schleifer made a point of signaling openness to external deals and, crucially, revealed that discussions with Sanofi about expanding the collaboration are already underway: “we have had productive early discussions with Sanofi to identify potential opportunities for further collaboration, including for several of Regeneron's Dupixent follow-on programs.” — Leonard Schleifer, President and Chief Executive Officer · 2026-07-30 This is a notable shift from a company that has historically preferred internal R&D. In the prior quarter, Len noted, “We are always open-minded to transactions certainly leveraging what we've built in terms of both development capabilities as well as commercial capabilities has merit to it.” — Leonard Schleifer, President and Chief Executive Officer · 2026-04-29 The new mention of concrete discussions suggests the possibility of a more formal partnership structure for next-generation I&I assets such as the long-acting IL-13 antibody and the "Supi-Dupi" molecule. When pressed on M&A appetite, Len directly pushed back on the perception of aversion:

I don't think I expressed an aversion to M&A. I think I expressed an aversion to overpaying in M&A settings.
Leonard Schleifer, President and Chief Executive Officer · 2026-07-30

His comments, combined with a ~$2.5B deployment in buybacks, dividends, and BD in the first half, indicate a disciplined but opportunistic capital allocation strategy. The company now has substantial dry powder—management cited $15.1B in cash and marketable securities net of debt—and is external opportunity hunting across the biopharma landscape.

Pipeline Catalysts and the Genetics-Driven Engine

The call also underscored the breadth of near-term catalysts. The C5 franchise is nearing several key readouts: an FDA decision for cemdisiran in generalized myasthenia gravis is expected in November, the PNH registrational data are due in Q4, and a geographic atrophy exploratory readout is also on deck. C5 antibody work, combined with the geographic atrophy program, could define a new standard of care. George Yancopoulos highlighted the differentiated mechanism in the PNH trial: “We strongly believe that improved control of intravascular hemolysis is the most relevant and validated endpoint.” — George Yancopoulos, President and Chief Scientific Officer · 2026-07-30 Meanwhile, the obesity portfolio—olatorepatide plus Praluent—is differentiated by its cardiovascular benefit, not just weight loss. George framed it as a "trojan horse" for cholesterol management, offering LDL reductions of 50–60% alongside weight loss. Importantly, this is not a one-trick pipeline. The company has roughly 50 active clinical programs, and management pointed to earlier-stage data in MASH, POTS, and a gene therapy for hearing loss. The Sanofi follow-ons—including productive early discussions—could bring these assets into a commercial engine that already knows how to launch blockbusters. As Len said, the company's strength is that it doesn't rely on any single program. In previous quarters, he had already signaled the potential of the next-generation Dupixent assets, noting, “we have also a lot of exciting follow on opportunities in this space particularly with our collection of what we hope will prove to be the best in class long acting IL 13...” — Leonard Schleifer, President and Chief Executive Officer · 2026-01-30

Why It Matters

For investors, the combination of a step-up in collaboration revenue, a clear-eyed management stance on BD, and a pipeline approaching a wave of data is an unusually constructive setup. The stock has been recovering—up 11.4% over the last 90 days—and the potential for a Sanofi partnership could re-rate the shares. With Sanofi collaboration revenue likely to inflect higher and multiple value-creating catalysts within the next 18 months, Regeneron appears to be entering a period where the long-awaited pipeline story may finally get the earnings support it needs. That is the story: a mature commercial business that is now turning to partnerships and a deep pipeline to write its next chapter.